| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aprea Therapeutics, Inc. (APRE) has 10 insiders with recent SEC Form 4 filings, including 10 buys and 1 sell. APRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 256.2K | $235.7K | - | |
| Dir | 45.8K | $42.1K | - | |
| CEO | 21.5K | $19.7K | - | |
| Dir | 10.2K | $9.4K | - | |
| Dir | 5.4K | $5.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 11, 2024 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Ofcr | Buy | 50 | $2.46 | $123.19 | +0.3% | +40.6% | -45.4% | |
| Oct 10, 2024 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Ofcr | Buy | 450 | $2.61 | $1,174.50 | +2.4% | +55.1% | -44.1% | |
| Mar 13, 2024 | Hamill John P. | Srvp/ Cfo/ Prin Fin &Acct Ofcr | Buy | 1,010 | $7.29 | $7,362.90 | +7.0% | -19.6% | -57.2% | |
| Mar 13, 2024 | Seizinger Bernd R.49 | Director | Buy | 6,860 | $7.29 | $50,009.40 | +25.6% | -19.6% | -57.2% | |
| Mar 13, 2024 | Henneman John B III | Director | Buy | 6,860 | $7.29 | $50,009.40 | +536.4% | -19.6% | -57.2% | |
| Mar 13, 2024 | Gilad Oren | President, CEO | Buy | 2,000 | $7.29 | $14,580.00 | +0.6% | -19.6% | -57.2% | |
| Jun 7, 2023 | Seizinger Bernd R.49 | Director | Buy | 10,097 | $3.66 | $36,956.55 | +27.6% | +9.0% | +32.5% | |
| May 18, 2022 | Schade Christian S | Chairman &CEO | Buy | 37,500 | $0.64 | $24,123.75 | +14.7% | +40.8% | -70.1% | |
| May 18, 2022 | Seizinger Bernd R.49 | Director | Buy | 50,000 | $0.71 | $35,500.00 | +18.6% | +40.8% | -70.1% | |
| Feb 28, 2022 | Attar Eyal C.85 | SVP, Chief Medical Officer | Sell | 36,000 | $1.73 | $62,280.00 | -43.4% | -51.9% | -85.3% |